TrialAnnals of oncology : official journal of the European Society for Medical Oncology2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

K Kalinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.